Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $19.00

Shares of Immatics N.V. (NASDAQ:IMTX) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $19.00.

Several research firms recently weighed in on IMTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Mizuho set a $25.00 target price on shares of Immatics in a research report on Thursday, February 19th. TD Cowen initiated coverage on shares of Immatics in a research report on Tuesday, April 28th. They set a “buy” rating on the stock. Jefferies Financial Group initiated coverage on shares of Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Wall Street Zen lowered shares of Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd.

Hedge Funds Weigh In On Immatics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Quarry LP bought a new position in Immatics during the fourth quarter valued at about $84,000. Insigneo Advisory Services LLC bought a new position in Immatics during the third quarter valued at about $103,000. Engineers Gate Manager LP bought a new position in Immatics during the second quarter valued at about $124,000. Finally, Fox Run Management L.L.C. bought a new position in Immatics during the fourth quarter valued at about $129,000. Institutional investors own 64.41% of the company’s stock.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $10.87 on Wednesday. Immatics has a fifty-two week low of $4.62 and a fifty-two week high of $12.41. The business has a 50-day moving average of $10.48 and a two-hundred day moving average of $10.16. The stock has a market capitalization of $1.46 billion, a P/E ratio of -5.46 and a beta of 1.31.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The business had revenue of $8.81 million for the quarter, compared to analyst estimates of $9.79 million. As a group, research analysts expect that Immatics will post -1.63 EPS for the current fiscal year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.